| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Immunotherapy for esophageal cancer: Where are we now and where can we go
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yoshiaki Shoji, Kazuo Koyanagi, Kohei Kanamori, Kohei Tajima, Mika Ogimi, Yamato Ninomiya, Miho Yamamoto, Akihito Kazuno, Kazuhito Nabeshima, Takayuki Nishi and Masaki Mori |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Kazuo Koyanagi, FACS, MD, PhD, Professor, Department of Gastroenterological Surgery, Tokai University School of Medicine, 143, Shimokasuya
, Isehara 259-1193, Kanagawa, Japan. kkoyanagi@tsc.u-tokai.ac.jp |
| Key Words |
Esophageal cancer; Immunotherapy; Immune checkpoint inhibitor; Programmed cell death-1; Anti-cytotoxic T-lymphocyte–associated protein 4; Neoadjuvant therapy; Adjuvant therapy; Clinical trials; Combination therapy |
| Core Tip |
Immune checkpoint inhibitor therapy alone or in combination with other cytotoxic agents has now become standard of care in the treatment of esophageal squamous cell carcinoma (ESCC) in metastatic and adjuvant settings, and has a high expectation to provide clinical benefit during perioperative period. In this editorial, we will discuss the existing evidence of immune-based treatments for ESCC, as well as recent clinical trials on various combinations with chemotherapy for different clinical settings including neoadjuvant, adjuvant, and metastatic diseases, which may provide future prospects of ESCC treatment for better patient outcomes. |
| Publish Date |
2024-05-20 09:15 |
| Citation |
<p>Shoji Y, Koyanagi K, Kanamori K, Tajima K, Ogimi M, Ninomiya Y, Yamamoto M, Kazuno A, Nabeshima K, Nishi T, Mori M. Immunotherapy for esophageal cancer: Where are we now and where can we go. <i>World J Gastroenterol</i> 2024; 30(19): 2496-2501</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i19/2496.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i19.2496 |
